Treatments · Glaucoma · Sustained-Release Drug Implant · Updated May 2026
Private iDose TR travoprost glaucoma implant, UK 2026
iDose TR is a tiny titanium reservoir filled with the prostaglandin analogue travoprost. A consultant glaucoma surgeon places it inside the front chamber of the eye in a minute or two via a small paracentesis; the device then releases travoprost continuously into the aqueous for many months, lowering intraocular pressure without the need for daily eye drops. It is licensed for adults with open-angle glaucoma and ocular hypertension and is particularly useful for patients who struggle with drop compliance, surface irritation or work and travel schedules that make daily dosing difficult. At CQC-registered UK centres in 2026, self-pay pricing is typically £4,000-£6,500 per eye per implant, depending on whether it is performed standalone or combined with cataract surgery or another MIGS procedure.
- Typical cost: £4,000-£6,500 per eye per implant (UK 2026).
- What it does: continuous travoprost release lowers IOP without daily drops.
- Best for: open-angle glaucoma or OHT with poor drop compliance or surface side effects.
- Procedure: in-clinic or theatre insertion, topical anaesthesia, minutes per eye.
- Re-dosing: a second implant can be placed when the first is depleted.
Private consultant glaucoma assessment: 0800 852 7782. Same-week appointments at CQC-registered UK clinics; transparent UK 2026 self-pay and insurer-billed pathways.
Fast answer: what is iDose TR and what does it cost?
iDose TR (Glaukos) is the first intraocular drug-delivery implant licensed to lower eye pressure in glaucoma. Instead of drops, the surgeon places a tiny titanium reservoir of travoprost inside your eye where it slowly releases the drug for many months. For many patients it means months — potentially years — of stable, drop-free IOP control. It is generally given to patients with open-angle glaucoma or ocular hypertension on one to three drops, particularly those who find drops irritating, inconvenient or hard to take reliably. It is often combined with cataract surgery to do both in one session.
Typical cost per eye
£4,000-£6,500 per implant (UK 2026).
Drug delivered
Travoprost (prostaglandin analogue), continuous release.
Duration
Sustained IOP lowering for many months (typically 6-12+).
Anaesthetic
Topical drops; minutes per eye.
Honest one-liner: iDose TR is the right choice when your glaucoma is well behaved on drops but the drops themselves are the problem — it does not replace surgery for advanced or refractory disease.
What is the iDose TR travoprost implant?
iDose TR is a small titanium drug-delivery platform developed by Glaukos and approved by the US FDA in December 2023 and progressively rolled out to international and UK private centres through 2024 to 2026. It comprises a tiny reservoir pre-loaded with the prostaglandin analogue travoprost and a membrane through which the drug elutes continuously into the aqueous humour of the eye. The platform anchors into the trabecular meshwork at the iridocorneal angle, where it sits unobtrusively and out of the visual axis.
The clinical idea is to take an extremely effective IOP-lowering drug — travoprost, the active in widely used eye drops — and deliver it directly inside the eye, at low and constant levels, free from the variability of patient drop technique, the surface side effects of preservatives, and the lash and lid changes that prostaglandin drops can cause externally. In practice, that means patients can stop or significantly reduce daily drops while their IOP remains controlled at a stable, low level.
In the UK, iDose TR is offered at selected private CQC-registered glaucoma centres in 2026, sometimes as a standalone procedure and often combined with cataract surgery or with another minimally invasive glaucoma surgery (MIGS) procedure. The aim is the same in either setting: better adherence, fewer side effects, and durable IOP control.
UK 2026 private iDose TR cost per eye
All-in self-pay quotes at CQC-registered UK clinics typically include consultant fees, theatre and hospital costs, the implant itself, and a defined package of follow-up visits to six months. Confirm whether glaucoma drops, if continued, are included.
What is included in a private iDose TR package?
Consultant glaucoma assessment
Best-corrected acuity, slit-lamp examination, gonioscopy of the iridocorneal angle, Goldmann applanation IOP, central corneal pachymetry, OCT of the retinal nerve fibre layer and automated visual field.
Drop and compliance review
A structured review of current drops, ocular surface symptoms, allergies, lifestyle barriers to adherence, and a realistic projection of likely benefit from a drug-delivery implant.
Theatre and surgeon fees
CQC-registered ophthalmic day-case theatre, consultant glaucoma surgeon and theatre team.
iDose TR device
The titanium travoprost-eluting implant itself and the proprietary delivery applicator.
Insertion procedure
Topical anaesthesia, paracentesis, gonio-prism-assisted placement into the trabecular meshwork and confirmation of position.
Follow-up to six months
Reviews at day 1, week 1, 1 month, 3 months and 6 months with IOP checks, OCT and visual field as needed, plus a structured drop-tapering plan.
What does the evidence say about iDose TR?
The pivotal evidence for iDose TR comes from two Phase 3 randomised clinical trials (GC-010 and GC-012), reported in peer-reviewed ophthalmology journals and presented at the American Academy of Ophthalmology and American Society of Cataract and Refractive Surgery meetings between 2022 and 2024, supporting the FDA approval in December 2023. In both trials, two doses of the iDose TR implant were compared with twice-daily timolol drops in patients with open-angle glaucoma or ocular hypertension.
The trials demonstrated non-inferior IOP lowering of around 6-8 mmHg from baseline through three months, with the slow-release iDose TR continuing to provide meaningful IOP reduction well beyond that, and around 80% of iDose TR-treated patients remaining off all topical pressure-lowering medication at 12 months in the higher-dose arm. Importantly, the implant was well tolerated, with low rates of ocular surface side effects and prostaglandin-associated periocular changes compared with drop arms, and the rate of clinically meaningful endothelial cell loss across the studied period was very low and comparable with control.
UK and European real-world series since approval have replicated those efficacy and safety findings in routine private and academic practice. Long-term durability beyond three years is still being characterised, but the device is designed to be re-dosed, and re-insertion procedures appear simple and safe.
iDose TR vs drops, SLT and MIGS
See our pages on iStent MIGS, OMNI canaloplasty, Hydrus Microstent, Preserflo MicroShunt, SLT laser and the broader drops-vs-SLT-vs-MIGS comparison, or our glaucoma treatments hub for the full menu.
Are you a candidate for iDose TR?
Good candidates
- Confirmed primary open-angle glaucoma or ocular hypertension.
- Open iridocorneal angle on gonioscopy.
- Currently on 1-3 IOP-lowering drops with adherence or surface side effects.
- Stable disease without rapid visual field progression.
- Adult, with adequate corneal endothelial cell density.
Better suited to other treatments
- Closed or narrow angle glaucoma.
- Advanced or rapidly progressive disease needing very low target IOP.
- Active uveitis or other intraocular inflammation.
- Low corneal endothelial cell density or Fuchs dystrophy.
- Prior complex anterior segment surgery limiting access to the trabecular meshwork.
Candidacy is decided after a structured glaucoma consultation that includes gonioscopy, OCT and visual field testing. Many patients start with a free initial online review before an in-person workup.
NHS vs private iDose TR in the UK
As of mid-2026, NHS access to iDose TR remains very limited in the UK. The device is licensed and CE-marked, and selected NHS tertiary glaucoma services have begun to use it in research and small-volume practice, but there is no nationwide NHS commissioning route. Most NHS patients with poor drop tolerance are offered selective laser trabeculoplasty, drop substitution, or, where appropriate, MIGS combined with cataract surgery.
The private route lets you choose a consultant glaucoma surgeon with a high implant case-load, have a full structured workup (gonioscopy, OCT, visual field) at the first visit, and proceed to treatment within a few weeks. Combined iDose TR plus phacoemulsification cataract surgery, or iDose TR plus a MIGS device in eyes that need both outflow improvement and pharmacological control, is straightforward to schedule in the private setting.
Insurance and funding
UK private medical insurers vary in their position on iDose TR. Where the device is used in a patient with documented intolerance or non-adherence to topical glaucoma drops and accepted clinical indication, several insurers (notably Bupa, AXA, Aviva and Vitality in 2026) will consider it on a case-by-case basis with prior authorisation. Other insurers may treat it as not yet routinely funded and request a self-pay arrangement. The clinic can usually liaise directly with your insurer once a consultant has confirmed indication.
For self-pay patients, transparent fixed quotes and finance plans are available; see our finance page and insured patients page, alongside our glaucoma surgery cost overview for context across the wider glaucoma menu.
Risks and limitations of iDose TR
- Transient IOP spike: mild pressure rises can occur in the early post-implant period and are managed with eye drops if needed.
- Iritis or anterior chamber inflammation: usually mild and short-lived, settled with topical steroids.
- Implant malposition: rare; correction or removal is occasionally needed.
- Corneal endothelial cell loss: low rates in trials but a theoretical concern; pre-implant cell density is checked.
- Drug depletion: after many months the IOP-lowering effect attenuates and re-implantation or drops may be required.
- Hyperaemia and conjunctival redness: some prostaglandin-class effects can still occur, although less than with daily drops.
- Endophthalmitis: a small (around 1 in 1,000-2,000) risk shared with any intraocular procedure.
Your surgeon will go through these and any individual factors in your case at consent, and you will be given a written, named contact route for urgent post-operative concerns.
Recovery timeline after iDose TR
First 24-48 hours
Mild gritty sensation; brief blur. Topical antibiotic and steroid drops; resume normal light activity the next day.
Week 1
First post-op IOP check; topical anti-inflammatory continues; many patients return to office work after 1-3 days.
Month 1-3
Most existing IOP-lowering drops can usually be tapered or stopped; IOP, OCT and field reviewed.
6-12 months
Sustained drop-free IOP control in most patients; structured surveillance for re-implant timing.
How to choose a UK iDose TR clinic
- Consultant glaucoma fellowship: the surgeon should have completed a glaucoma fellowship and perform MIGS, drainage surgery and laser routinely.
- Documented iDose TR case-load: ask how many implants they have placed and their drop-reduction rates.
- Structured workup capacity: in-house OCT, visual fields and gonioscopy by an experienced examiner.
- Full menu of glaucoma options: the clinic should also offer SLT, MIGS, Preserflo and trabeculectomy so the right treatment is offered.
- CQC registration: day-case theatres should be CQC-registered with full anaesthetic capability.
- Written package: a transparent, fixed quote that includes the implant device, theatre, follow-up and re-implant pricing.
For an independent assessment of whether iDose TR is right for your glaucoma, request a free initial online consultation or make an in-person appointment.
iDose TR frequently asked questions
How long does an iDose TR implant last?
In the Phase 3 trials, around 80% of eyes treated with the higher-dose iDose TR remained off all topical pressure-lowering medication at 12 months, with IOP-lowering effect continuing for many months beyond. The exact duration in an individual patient depends on baseline pressure and outflow physiology.
Will I be able to stop my glaucoma drops?
Many patients on one to two drops can stop them entirely after iDose TR, with the surgeon supervising a structured drop-taper over the first 1-3 months. Some patients on heavier multi-drop regimes can reduce to a single agent rather than fully discontinue.
Can the implant be removed if I do not get on with it?
Yes. The device is designed to be removed by a glaucoma surgeon if necessary, and explantation is a brief intracameral procedure. In practice, intolerance leading to explantation is uncommon.
What happens when the implant runs out?
As travoprost release tails off, IOP may begin to rise. A second iDose TR implant can be placed alongside the first to restore drop-free control, or topical drops can be restarted, depending on patient preference and clinical context.
Can iDose TR be combined with cataract surgery?
Yes, frequently. Combined phacoemulsification cataract surgery with intraocular lens implantation and iDose TR placement in the same session is well established and means one operation, one recovery and one set of post-op visits.
Does iDose TR cause the same lash and eyelid changes as prostaglandin drops?
Because the drug is released directly inside the eye at low constant levels rather than landing on the lid and ocular surface, periocular prostaglandin-associated changes (darkening, lash growth, orbital fat atrophy) are far less common than with daily topical prostaglandin drops.
Does it hurt?
Insertion is performed under topical anaesthetic drops and most patients feel pressure and see lights rather than pain. There is a mild gritty sensation and watering for a day or two after, which settles.
Will my eye look different?
No. The implant sits inside the anterior chamber angle, out of the visual axis and not visible to others. A glaucoma specialist using a gonio lens can see it on examination.
How does iDose TR compare with SLT laser?
Both reduce dependence on drops. SLT works by laser-stimulating trabecular outflow and is non-pharmacological; effect typically lasts 3-5 years and can be repeated. iDose TR delivers a powerful drug locally for many months and is particularly useful in patients who need stronger IOP lowering than SLT alone provides.
Is iDose TR an alternative to filtration surgery?
For most patients with mild-moderate glaucoma where filtration surgery would be too much, iDose TR is a less invasive alternative to keep IOP controlled. For advanced or refractory disease requiring very low target IOP, filtration surgery such as Preserflo MicroShunt or trabeculectomy remains the gold standard.
Is iDose TR safe for the cornea?
Pre-implant assessment includes corneal pachymetry and specular microscopy where indicated to confirm a healthy endothelium. Long-term endothelial cell loss in trials was low and comparable with control arms; patients with low cell density or Fuchs dystrophy are usually steered to alternatives.
Will my private medical insurance pay for iDose TR?
Several major UK insurers consider iDose TR on a case-by-case basis with prior authorisation when there is documented intolerance or poor adherence to topical drops. Other insurers may treat it as not yet routinely funded and require a self-pay arrangement; the clinic can liaise with your insurer.
When should I start glaucoma surgery rather than just changing drops?
If your IOP is high despite drops, if drops are causing significant side effects, or if you are not taking them reliably, it is worth discussing surgical or device-based options. iDose TR sits between SLT/MIGS and full filtration surgery and is particularly suited to patients whose problem is mainly with drop adherence rather than uncontrolled disease.
Methodology and sources
UK 2026 self-pay pricing on this page reflects published private fees from CQC-registered ophthalmic providers and consultant glaucoma services at the time of last review (May 2026), expressed as typical per-eye ranges rather than fixed prices. Clinical content has been written by the Eye Surgery Clinic editorial team, reviewed by a UK GMC-registered consultant ophthalmologist with glaucoma fellowship training. Evidence is drawn from the Glaukos GC-010 and GC-012 Phase 3 randomised trials, the US FDA approval documentation (December 2023), European Glaucoma Society and Royal College of Ophthalmologists professional guidance, and emerging UK real-world series. Page last reviewed 23 May 2026 against the live URL set on eyesurgeryclinic.co.uk.
Book a consultant glaucoma assessment
Find out whether the iDose TR travoprost implant is right for your glaucoma with a same-week consultant appointment, full structured workup and a transparent UK 2026 quote.
Or call 0800 852 7782.
Back to Treatments